Risk Stratification of Thymic Epithelial Tumors by Using a Nomogram Combined with Radiomic Features and TNM Staging
Overview
Authors
Affiliations
Objectives: To construct and validate a nomogram model that integrated the CT radiomic features and the TNM staging for risk stratification of thymic epithelial tumors (TETs).
Methods: A total of 136 patients with pathology-confirmed TETs who underwent CT examination were collected from two institutions. According to the WHO pathological classification criteria, patients were classified into low-risk and high-risk groups. The TNM staging was determined in terms of the 8th edition AJCC/UICC staging criteria. LASSO regression was performed to extract the optimal features correlated to risk stratification among the 704 radiomic features calculated. A nomogram model was constructed by combining the Radscore and the TNM staging. The clinical performance was evaluated by ROC analysis, calibration curve, and decision curve analysis (DCA). The Kaplan-Meier (KM) analysis was employed for survival analysis.
Results: Five optimal features identified by LASSO regression were employed to calculate the Radscore correlated to risk stratification. The nomogram model showed a better performance in both training cohort (AUC = 0.84, 95%CI 0.75-0.91) and external validation cohort (AUC = 0.79, 95%CI 0.69-0.88). The calibration curve and DCA analysis indicated a better accuracy of the nomogram model for risk stratification than either Radscore or the TNM staging alone. The KM analysis showed a significant difference between the two groups stratified by the nomogram model (p = 0.02).
Conclusions: A nomogram model that integrated the radiomic signatures and the TNM staging could serve as a reliable model of risk stratification in predicting the prognosis of patients with TETs.
Key Points: • The radiomic features could be associated with the TET pathophysiology. • TNM staging and Radscore could independently stratify the risk of TETs. • The nomogram model is more objective and more comprehensive than previous methods.
Yang Y, Cheng J, Chen L, Cui C, Liu S, Zuo M Thorac Cancer. 2024; 15(31):2235-2247.
PMID: 39305057 PMC: 11543273. DOI: 10.1111/1759-7714.15454.
Yamada D, Kojima F, Otsuka Y, Kawakami K, Koishi N, Oba K BMJ Open Respir Res. 2024; 11(1).
PMID: 38589197 PMC: 11015206. DOI: 10.1136/bmjresp-2023-002249.
Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures.
Zhang X, Zhang P, Cong A, Feng Y, Chi H, Xia Z Front Immunol. 2023; 14:1264325.
PMID: 37849766 PMC: 10577431. DOI: 10.3389/fimmu.2023.1264325.
Lu X, Zhu T BMC Med Imaging. 2023; 23(1):115.
PMID: 37644397 PMC: 10466844. DOI: 10.1186/s12880-023-01083-6.
Li Y, Jiang A, Zhao Y, Shi C, Ma Y, Fu X Front Endocrinol (Lausanne). 2022; 13:1050364.
PMID: 36561557 PMC: 9763871. DOI: 10.3389/fendo.2022.1050364.